Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 436Thoracic 190Gastrointestinal 163Gynecologic 148Head & Neck 125Genitourinary 112Dermatologic 74Sarcoma 27Other solid neoplasm 24Lymphoid 15CNS 10Endocrine 5Other hematologic neoplasm 4Plasma cell 2NET 1

Conditions

Neuroendocrine Tumors 117Gastro-enteropancreatic neuroendocrine tumor 21Neoplasms 20Carcinoid Tumor 17Colorectal Neoplasms 13Carcinoma, Neuroendocrine 11Neoplasm Metastasis 10Carcinoma 10Lung Neoplasms 9Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Sarcoma 7Pancreatic Neoplasms 7Carcinoma, Hepatocellular 7Adenoma, Islet Cell 7Stomach Neoplasms 6Serotonin Syndrome 6Pheochromocytoma 6Melanoma 6Head and Neck Neoplasms 6Digestive System Neoplasms 6Cholangiocarcinoma 6Thyroid Neoplasms 5Paraganglioma 5Ovarian Neoplasms 5Gastroenteropancreatic Neuroendocrine Tumors 5Colonic Neoplasms 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Breast Neoplasms × NET × Clear all
NCT06577987 2025-09-15

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Circle Pharma

Phase 1 Recruiting
220 enrolled
BreastEndocrineNETThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡